[Rejection antigens of tumors and specific immunotherapy of cancer].
Human tumors carry antigens that are recognized by the patients' cytolytic T lymphocytes. An important group of antigens is coded by the MAGE family of genes. These antigens are expressed in a significant proportion of tumors of numerous histological types but not in normal tissues. Clinical trials are underway in an attempt to immunize patients suffering from metastatic melanomas using peptides coded by the MAGE genes. Regressions have been observed in 5 of the 17 immunized patients.
Boon
T
T
Institut Ludwig pour la recherche sur le cancer, branche de Bruxelles, l'Université catholique de Louvain.
Lucas
S
S
D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology; D008545:Melanoma / Q000235:genetics / Q000628:therapy; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000235:genetics / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000951:Antigens, Neoplasm; C072011:MAGEA1 protein, human; C072013:MAGEA3 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins
Antigènes de rejet des tumeurs et immunothérapie spécifique du cancer.